NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2024, Vol. 36 ›› Issue (1): 137-154. doi: 10.16333/j.1001-6880.2024.1.016

Previous Articles     Next Articles

Medication rule analysis and pharmacological analysis of traditional Chinese medicine treating allergic rhinitis based on data mining,network pharmacology and experimental validation

WANG Xiao-yu1,WANG Zhao1,CAO Li-hua1,HE Hong-juan1,WANG Zhen-zhen1,LI Xiu-min2,MIAO Ming-san1*   

  1. 1 Academy of Chinese Medical Sciences,Henan University of Chinese Medicine,Zhengzhou 450046,China;2Microbiology and Immunology,New York Medical College,New York 10595,USA
  • Online:2024-01-23 Published:2024-01-23

Abstract:

The full-text search was conducted with “traditional Chinese medicine (TCM)+allergic rhinitis” theme in CNKI, Wanfang and VIP database.The literature published from January 2000 to February 2022 were selected,and clinical TCM prescriptions for AR were collected under “inclusion and exclusion” criteria.The statistics processing of drug frequency,dosage,flavor,property, channel tropism,efficacy and association rule analysis were carried out.A total of 252 TCM prescriptions were obtained, including 223 different Chinese medicines.And there were 21 Chinese medicines used in the treatment of AR with high frequency ≥ 30,mainly with exterior-releasing and supplementing efficacies.Warm and pungent were main flavors among high-frequency TCM.In association rule analysis,21 combinations of TCM with high frequency ≥ 64 were found out;among them,Huangqi-Xinyi drug pair was utilized in the highest frequency.The network pharmacological analysis indicated that Huangqi-Xinyi has 48 active compounds and 306 corresponding protein targets,including PTGS2,HSP90,CALM1,NOS2,and CHRM1.Go and KEGG analysis revealed that core targets predominantly effected on AR by responsing to xenobiotic stimulus,oxidoreductase activity,neuroactive ligand-receptor interaction and calcium signaling pathway.Molecular docking results showed that Huangqi-Xinyi drug pair probably treated AR by acting on PTGS2,CHRM1,CYP1B1 targets through asarinin,formononetin,kaempferol and quercetin.In vivo experiment showed that Huangqi-Xinyi drug pair effectively decreased the level of histamine,total IgE,RW-specific IgE,TNF-α and IL-6 in serum,nasal lavage fluid and bronchoalveolar lavage fluid of AR mice,and increased the level of anti-inflammatory factor IL-10 in above-mentioned serum and fluids.Also,Huangqi-Xinyi drug pair significantly decreased rubbing and sneezing times of AR mice and inhibited the protein expression of PTGS2,HSP90 and NOS2.Thus,this study clarified that Huangqi-Xinyi drug pair had a therapeutic effect on AR by inhibiting HSP90/PTGS2/NOS2 pathway,thereby inhibited inflammation and relieved rubbing and sneezing symptoms of AR mice.

Key words: allergic rhinitis, medication rule, association rule, network pharmacology, molecular docking, in vivo experiment

CLC Number: